Aria Kicks off Clinical Trial for Non-Invasive Down Syndrome Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aria Diagnostics said today that it has begun a blinded, multicenter clinical trial that will compare its non-invasive prenatal trisomy 21 screening test with standard screening methods.

The company's test, which is still in development, is based on a sequencing-based method that analyzes cell-free DNA in maternal blood to detect fetal chromosomal abnormalities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.